Moderna Faces Stock Price Pressure Amid Sales Forecast Cuts

Moderna struggles as its stock tumbles 79%. The decline follows lowered revenue guidance for 2024 and 2025. Investors are concerned about competitive pressures and diminished vaccine sales, prompting questions on whether the stock is undervalued.

Date: 16-01-2025

AI Rating: 4

Earnings Per Share (EPS)
No direct information about EPS was provided in the text.
Revenue Growth
Moderna's revenue guidance for 2024 was adjusted to between $3 billion and $3.1 billion from a previous range of $3 billion to $3.5 billion. Additionally, the 2025 revenue is now expected to be between $1.5 billion and $2.5 billion, which represents approximately a 50% reduction in revenue expectations from the lower end of the previous guidance. This signifies strong negative sentiment, as investors were anticipating growth when the mRESVIA vaccine was approved.
Net Income
No specific net income figures were mentioned in the text.
Profit Margins
No profit margins (gross, operating, net) information was provided in the text.
Free Cash Flow (FCF)
No information regarding free cash flow was found.
Return on Equity (ROE)
No details about return on equity were present in the text.
In conclusion, Moderna is experiencing significant downward pressure on its stock due to lowered revenue projections and increasing competition in the vaccine market. The decrease in its sales outlook is alarming, particularly given that the pandemic-era success did not translate into sustained revenue growth. Competing products in the RSV vaccine sector further complicate Moderna's recovery. Despite a promising pipeline with potential future vaccines, the current forecast raises critical concerns for investors. The text suggests that while the stock may appear inexpensive at current levels, the risks involved should not be underestimated for investors with lower risk tolerance.

Stocks: MRNA PFE GSK